ZNF683 marks a CD8+ T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome

Erin M. Parry(Broad Institute), Camilla K. Lemvigh(Dana-Farber Cancer Institute), Stephanie Deng(Dana-Farber Cancer Institute), Nathan Dangle(Dana-Farber Cancer Institute), Neil Ruthen(Dana-Farber Cancer Institute), Binyamin A. Knisbacher(Broad Institute), Julien Broséus(Inserm), Sébastien Hergalant(Inserm), Romain Guièze(Université Clermont Auvergne), Shuqiang Li(Broad Institute), Wandi Zhang(Dana-Farber Cancer Institute), Connor Johnson(Broad Institute), Jaclyn M. Long(Broad Institute), Shanye Yin(Dana-Farber Cancer Institute), Lillian Werner(Dana-Farber Cancer Institute), Annabelle Anandappa(Dana-Farber Cancer Institute), Noelia Purroy(Dana-Farber Cancer Institute), Satyen H. Gohil(Dana-Farber Cancer Institute), Giacomo Oliveira(Harvard University), Pavan Bachireddy(The University of Texas MD Anderson Cancer Center), Sachet A. Shukla(The University of Texas MD Anderson Cancer Center), Teddy Huang(Dana-Farber Cancer Institute), Joseph D. Khoury(University of Nebraska Medical Center), Beenu Thakral(The University of Texas MD Anderson Cancer Center), Michael Dickinson(The Royal Melbourne Hospital), Constantine S. Tam(Monash Health), Kenneth J. Livak(Dana-Farber Cancer Institute), Gad Getz(Broad Institute), Donna Neuberg(Dana-Farber Cancer Institute), Pierre Feugier(Inserm), Peter V. Kharchenko(Harvard University), William G. Wierda(The University of Texas MD Anderson Cancer Center), Lars Rønn Olsen(Technical University of Denmark), Nitin Jain(The University of Texas MD Anderson Cancer Center), Catherine J. Wu(Broad Institute)
Cancer Cell
September 21, 2023
Cited by 71Open Access
Full Text

Abstract


Related Papers